What day did you get it in the mail? Should I assume I'm not getting one if I have not received yet? Thanks
Cephalon Contract
- Thread starter Anonymous
- Start date
-
- Tags
- None
I was gone all weekend so it came either Friday or Saturday. I think mine actually came Friday b/c it came in an envelope just like our pay stubs do every 2 weeks.
hard check on friday and so did the other 5 people that got laid off in my district. I think your assumption is correct sorry
I usually get my pay stub on Monday, is it possible it will come then?
I think so. Are you on the West Coast? Good luck.
Go out get the mail and LOOKIE LOOKIE a check from Inventiv for bonus. I did not expect this to tell you the truth. I really needed it. Nice surprise on a tuesday.
109 million for Amrix last year, and I barely made 5K in bonus. WTF!!!!! my territory is in north east so I makes a lot in terms of dollar sales. Total crap!
Cephalon Wins Order in Patent Suit Delaying Sales of Generic Form of Amrix
By Susan Decker and Phil Milford - Apr 8, 2011 3:28 PM ET
inShare
More Print Email
Cephalon Inc. (CEPH) won a court order that prevents generic-drug makers from selling low-cost versions of its muscle relaxant Amrix until a judge rules on a patent dispute over the drug.
Generic versions could have entered the market as soon as April 17. U.S. District Judge Sue Robinson in Wilmington, Delaware, said today she wasn’t sure if she would be able to issue a ruling on the case by that date.
“It is the court’s intention to issue its findings of fact and conclusions of law in short order, but not necessarily by April 17,” Robinson wrote in court papers.
The consolidated case relates in part to a lawsuit filed in Delaware in January 2009 by Frazer, Pennsylvania-based Cephalon against Impax Laboratories Inc. (IPXL) of Hayward, California. Cephalon alleges infringement of a 2008 patent for the drug, known chemically as cyclobenzaprine hydrochloride. That individual case was settled last year.
“We’re pleased with the judge’s ruling that prevents generic companies from marketing a generic version of Amrix before the court has fully decided the patent-infringement lawsuit,” Natalie de Vane, a Cephalon spokeswoman, said in a phone interview.
Cephalon reported $109.2 million in U.S. Amrix sales last year.
The combined case is In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation, 09-md-2118, U.S. District Court, District of Delaware (Wilmington).
To contact the reporters on this story: Susan Decker in Washington at sdecker1@bloomberg.net; Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net
To contact the editors responsible for this story: Michael Hytha at mhytha@bloomberg.net; Allan Holmes at aholmes25@bloomberg.net
Cephalon Wins Order in Patent Suit Delaying Sales of Generic Form of Amrix
By Susan Decker and Phil Milford - Apr 8, 2011 3:28 PM ET
inShare
More Print Email
Cephalon Inc. (CEPH) won a court order that prevents generic-drug makers from selling low-cost versions of its muscle relaxant Amrix until a judge rules on a patent dispute over the drug.
Generic versions could have entered the market as soon as April 17. U.S. District Judge Sue Robinson in Wilmington, Delaware, said today she wasn’t sure if she would be able to issue a ruling on the case by that date.
“It is the court’s intention to issue its findings of fact and conclusions of law in short order, but not necessarily by April 17,” Robinson wrote in court papers.
The consolidated case relates in part to a lawsuit filed in Delaware in January 2009 by Frazer, Pennsylvania-based Cephalon against Impax Laboratories Inc. (IPXL) of Hayward, California. Cephalon alleges infringement of a 2008 patent for the drug, known chemically as cyclobenzaprine hydrochloride. That individual case was settled last year.
“We’re pleased with the judge’s ruling that prevents generic companies from marketing a generic version of Amrix before the court has fully decided the patent-infringement lawsuit,” Natalie de Vane, a Cephalon spokeswoman, said in a phone interview.
Cephalon reported $109.2 million in U.S. Amrix sales last year.
The combined case is In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation, 09-md-2118, U.S. District Court, District of Delaware (Wilmington).
To contact the reporters on this story: Susan Decker in Washington at sdecker1@bloomberg.net; Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net
To contact the editors responsible for this story: Michael Hytha at mhytha@bloomberg.net; Allan Holmes at aholmes25@bloomberg.net
Walking Eagle
Active Member
- Walking Eagle Apr 10, 2011 at 09:38: PM
Walking Eagle
Active Member
Amrix patent is safe. Cephalon is saved!! The contract is saved!!